Related Experiment Video
Updated: Jun 14, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit
E A Dizdar1, C Aydemir, O Erdeve
1Neonatal Intensive Care Unit, Zekai Tahir Burak Women's Health and Education Hospital, Hamamonu, Ankara, Turkey. drevrim@yahoo.com
Insights
This study details a large respiratory syncytial virus (RSV) outbreak in a neonatal intensive care unit (NICU). Early detection via rapid testing and palivizumab prophylaxis helped control the RSV spread in high-risk infants.
Area of Science:
- Neonatal Medicine
- Infectious Disease Epidemiology
- Pediatric Pulmonology
Background:
- Palivizumab is approved for preventing respiratory syncytial virus (RSV) in high-risk infants but not routinely recommended for NICU outbreaks.
- Neonatal intensive care units (NICUs) are vulnerable to RSV outbreaks, posing significant risks to premature infants.
Purpose of the Study:
- To report on the early detection and management of an RSV outbreak in a NICU setting.
- To evaluate the effectiveness of rapid antigen testing and palivizumab prophylaxis in controlling RSV spread within a NICU.
Main Methods:
- An RSV outbreak in a NICU was detected using a rapid antigen test (Respi-Strip((R))) during a screening trial.
- Palivizumab prophylaxis was administered to 37 premature infants following initial RSV detections.
- Infection control measures were implemented alongside palivizumab treatment.
Main Results:
- Eleven preterm infants initially tested positive for RSV.
- Two additional asymptomatic cases were identified through further screening.
- Two symptomatic cases were detected post-palivizumab administration, indicating limited treatment efficacy in already infected infants.
Conclusions:
- This represents a large RSV outbreak in a NICU identified early through rapid testing.
- Infection control measures combined with palivizumab prophylaxis were effective in controlling the outbreak.
- Early detection and intervention are crucial for managing RSV outbreaks in vulnerable neonatal populations.
Abstract:
Palivizumab is currently licensed for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children with chronic lung disease, with a history of preterm birth, or with haemodynamically significant congenital heart disease, but its routine use during outbreaks in neonatal intensive care units (NICUs) is not currently recommended. Here we report an outbreak in a NICU detected during a screening trial for RSV infection using a rapid antigen test (Respi-Strip((R))). Eleven preterm infants in our NICU tested positive for RSV during January 2009. Subsequent testing of the remaining infants in the NICU revealed two additional asymptomatic cases. In addition to precautions against cross-infection, palivizumab prophylaxis was administered to the remaining 37 premature infants. Two days after treatment, RSV was detected in two additional infants who had become symptomatic. To our knowledge this is the largest RSV outbreak in a NICU to be identified at an early stage by rapid testing and effectively controlled by infection control measures and palivizumab prophylaxis.
More Related Videos
Related Concept Videos
Respiratory Syncytial Virus Disease
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-III
Acute Respiratory Failure-IV

